Published in Radiology on April 11, 2013
MRI Versus PSA in Prostate Cancer Screening (MVP) | NCT02799303
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol (2014) 1.55
Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer. Biomed Res Int (2013) 1.24
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology (2014) 1.13
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol (2013) 1.02
Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol (2014) 0.96
Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol (2014) 0.94
MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol (2013) 0.93
The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer. World J Urol (2014) 0.91
Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided. Biomed Res Int (2014) 0.90
Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest. World J Urol (2015) 0.90
Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications. Acad Radiol (2016) 0.89
The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol (2015) 0.89
Prostate cancer: MRI/US-guided biopsy--a viable alternative to TRUS-guidance. Nat Rev Urol (2013) 0.86
Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes. Curr Urol Rep (2016) 0.86
Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol (2015) 0.85
Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol (2016) 0.84
Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am (2014) 0.83
Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. Eur Urol (2015) 0.83
Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. World J Urol (2014) 0.83
Open-source image registration for MRI-TRUS fusion-guided prostate interventions. Int J Comput Assist Radiol Surg (2015) 0.80
Magnetic resonance imaging-guided prostate biopsy: present and future. Korean J Radiol (2015) 0.80
Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol (2016) 0.80
Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. J Urol (2016) 0.79
Preoperative prostate biopsy and multiparametric magnetic resonance imaging: reliability in detecting prostate cancer. Int Braz J Urol (2015) 0.79
Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL. Yonsei Med J (2016) 0.79
Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score. World J Urol (2016) 0.78
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
The utility and limitations of contrast-enhanced ultrasound for the diagnosis and treatment of prostate cancer. Sensors (Basel) (2015) 0.78
Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. Urology (2015) 0.78
Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int (2014) 0.77
False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging (2015) 0.77
Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion. World J Urol (2013) 0.77
Optimizing safety and accuracy of prostate biopsy. Curr Opin Urol (2016) 0.77
The changing role of imaging in clinical care. Nat Rev Urol (2014) 0.77
Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists. Korean J Urol (2015) 0.76
Is visual registration equivalent to semiautomated registration in prostate biopsy? Biomed Res Int (2015) 0.76
The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol (2015) 0.76
Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. World J Urol (2016) 0.76
MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience. Int Urol Nephrol (2016) 0.75
Magnetic resonance imaging - ultrasound fusion targeted biopsy outperforms standard approaches in detecting prostate cancer: A meta-analysis. Mol Clin Oncol (2016) 0.75
Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers. PLoS One (2017) 0.75
Comparison of prostate MRI-3D transrectal ultrasound fusion biopsy for first-time and repeat biopsy patients with previous atypical small acinar proliferation. Can Urol Assoc J (2016) 0.75
Accuracy of Elastic Fusion of Prostate Magnetic Resonance and Transrectal Ultrasound Images under Routine Conditions: A Prospective Multi-Operator Study. PLoS One (2016) 0.75
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone. BMC Med Imaging (2017) 0.75
Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. Can Urol Assoc J (2015) 0.75
Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study. Indian J Urol (2017) 0.75
1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer. Clujul Med (2017) 0.75
Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. World J Urol (2015) 0.75
Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urol Pract (2014) 0.75
Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms. World J Urol (2016) 0.75
Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Curr Urol Rep (2017) 0.75
Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. World J Urol (2015) 0.75
Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study. Eur Radiol (2017) 0.75
Molecular imaging and fusion targeted biopsy of the prostate. Clin Transl Imaging (2016) 0.75
From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy. Int Urol Nephrol (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int (2011) 2.41
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol (2008) 2.32
Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology (2009) 2.16
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Grade 2 meningioma and radiosurgery. J Neurosurg (2015) 2.02
Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol (2006) 1.99
Determination of renal stone composition with dual-energy CT: in vivo analysis and comparison with x-ray diffraction. Radiology (2010) 1.99
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res (2002) 1.97
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology (2010) 1.77
Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro- or suprahepatic caval thrombus. BJU Int (2006) 1.71
Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol (2003) 1.68
Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate (2009) 1.66
Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol (2002) 1.60
Efficacy of the InVance male sling in men with stress urinary incontinence. Eur Urol (2006) 1.58
Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol (2008) 1.57
Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care (2010) 1.56
Results of endoluminal occlusion of the inferior vena cava during radical nephrectomy and thrombectomy. Eur Urol (2008) 1.55
Predictors of extubation failure in patients with chronic obstructive pulmonary disease. J Crit Care (2006) 1.54
Conservative management of upper urinary tract tumors. Eur Urol (2002) 1.53
Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol (2007) 1.53
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int (2014) 1.49
Seasonality of serum prostate-specific antigen levels: a population-based study. Eur Urol (2006) 1.48
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med (2006) 1.46
Mass screening for retrocochlear disorders: low-field-strength (0.2-T) versus high-field-strength (1.5-T) MR imaging. AJNR Am J Neuroradiol (2002) 1.45
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res (2007) 1.45
Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results. Ultrasound Med Biol (2003) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41
Vascular graft infections in the intensive care unit: clinical spectrum and prognostic factors. J Infect (2010) 1.40
To infinity and beyond: the robotic toy story. Eur Urol (2011) 1.40
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res (2006) 1.39
Rapidly destructive osteoarthritis of the hip: MR imaging findings. AJR Am J Roentgenol (2002) 1.39
[Can a standard treatment be proposed for penile cancer?]. Prog Urol (2007) 1.39
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol (2008) 1.35
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist (2012) 1.34
Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet (2013) 1.34
Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int (2009) 1.29
Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology (2014) 1.28
Schwannoma of the sinonasal tract: a clinicopathologic and immunohistochemical study of 5 cases. Arch Pathol Lab Med (2003) 1.28
Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab (2013) 1.27
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet (2007) 1.27
Natural history and treatment of bone complications in prostate cancer. Eur Urol (2006) 1.26
Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol (2009) 1.25
MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res (2009) 1.24
Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch (2003) 1.23
Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol (2006) 1.23
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol (2009) 1.18
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol (2013) 1.17
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15
Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. Urology (2011) 1.15
Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology (2004) 1.14
Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis (2005) 1.12